Discovering Therapeutics With AI
insitro combines high-throughput cell biology, human genetics, and machine learning to identify causal disease drivers and design targeted therapeutics.
Discover Transformative Therapeutics and Innovative Discoveries
insitro combines automated high-throughput cell biology, human genetics, and machine learning to identify causal disease drivers and design targeted therapeutics.
High-Throughput Biology
Leveraging automated cell biology platforms to generate massive biological datasets efficiently.
Human Genetics
Uncovering disease insights and causal drivers using advanced genetic analysis.
Machine Learning
Applying predictive modeling and AI algorithms to design targeted therapeutics effectively.
Pioneering AI-Driven Therapeutics
We combine automated high-throughput cell biology, human genetics, and machine learning to identify causal disease drivers and design targeted therapies.
Cell Biology
Automated high-throughput cellular assays for deep biological insights.
Human Genetics
Leveraging vast genetic data to uncover novel disease targets.
Machine Learning
Advanced algorithms designed to model complex biological systems.
Pioneering Therapeutics Through AI and Biology
Founded in 2018 by Daphne Koller and headquartered in South San Francisco, insitro integrates automated high-throughput cell biology, human genetics, and machine learning. Our mission is to discover causal disease drivers and design targeted therapeutics to transform patient care.
Our Process
We combine automated high-throughput cell biology, human genetics, and machine learning to drive discovery.
Cellular Biology
Automated high-throughput cell biology generates robust functional data at scale.
Human Genetics
Advanced analytics uncover causal disease drivers from complex genomic datasets.
Machine Learning
Predictive models are trained to design targeted therapeutics effectively.
Accelerating Drug Discovery Through Machine Learning
Discover our core pillars combining advanced cellular biology and artificial intelligence.
2018
Founded Year
Established in South San Francisco to transform therapeutic development.
100
Cell Models
Automated high-throughput platforms generating rich biological data.
50
Disease Drivers
Identifying novel targets for truly transformative targeted medicines.
